Cargando…

Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study

BACKGROUND: With advancement in the treatment options of rheumatoid arthritis (RA), optimising the outcomes of difficult-to-treat patients has become increasingly important in clinical practice. In particular, insensitivity to first-line biologic disease-modifying anti-rheumatic drugs (bDMARD) is be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ochi, Sae, Saito, Kazuyoshi, Mizoguchi, Fumitaka, Kato, Shigeaki, Tanaka, Yoshiya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057565/ https://www.ncbi.nlm.nih.gov/pubmed/32131890 http://dx.doi.org/10.1186/s13075-020-2122-5

Ejemplares similares

Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
por: Ochi, Sae, et al.
Publicado: (2022)

Rheumatoid arthritis
por: Tanaka, Yoshiya
Publicado: (2020)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis
por: Hueber, Wolfgang, et al.
Publicado: (2009)

Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study
por: Katsuyama, Takayuki, et al.
Publicado: (2014)

Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors
por: Han, Xue, et al.
Publicado: (2021)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

Signal transduction inhibitors for the treatment of rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2012)

Current concepts in the management of rheumatoid arthritis
por: Tanaka, Yoshiya
Publicado: (2016)

Role of DNA dioxygenase Ten-Eleven translocation 3 (TET3) in rheumatoid arthritis progression
por: Kawabe, Akio, et al.
Publicado: (2022)

Association between ultrasound images and patient-reported outcomes in the treatment of rheumatoid arthritis: a retrospective study
por: Nawata, Masao, et al.
Publicado: (2021)

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
por: Massey, Jonathan, et al.
Publicado: (2018)

Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
por: Glossop, John R, et al.
Publicado: (2005)

Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis
por: Virone, Alexandre, et al.
Publicado: (2019)

Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor
por: Ernestam, Sofia, et al.
Publicado: (2006)

Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis
por: Giollo, Alessandro, et al.
Publicado: (2021)

IL-6 production through repression of UBASH3A gene via epigenetic dysregulation of super-enhancer in CD4(+) T cells in rheumatoid arthritis
por: Yamagata, Kaoru, et al.
Publicado: (2022)

Phase II/III Results of a Trial of Anti–Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2022)

Correction: IL-6 production through repression of UBASH3A gene via epigenetic dysregulation of super-enhancer in CD4+ T cells in rheumatoid arthritis
por: Yamagata, Kaoru, et al.
Publicado: (2022)

Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview
por: Tanaka, Yoshiya
Publicado: (2021)

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
por: Pappas, Dimitrios A, et al.
Publicado: (2021)

Anti-tumour necrosis factor therapy modulates the OPG/OPGL system in rheumatoid arthritis synovium
por: Catrina, AI, et al.
Publicado: (2004)

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
por: Weitz, Jeffrey I, et al.
Publicado: (2022)

Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2015)

Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain
por: Hidalgo-Vega, Álvaro, et al.
Publicado: (2015)

Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor–methotrexate combination therapy versus triple therapy in rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors
por: Tanaka, Toshio, et al.
Publicado: (2014)

Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies
por: Genovese, Mark C., et al.
Publicado: (2021)

Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis
por: Cacciapaglia, Fabio, et al.
Publicado: (2016)

Tumour Necrosis Factor-α Inhibition Improves Stroke Outcome in a Mouse Model of Rheumatoid Arthritis
por: Bonetti, N. R., et al.
Publicado: (2019)

Tumour necrosis factor gene polymorphisms in Egyptian patients with rheumatoid arthritis and their relation to disease activity and severity
por: Zaghlol, Heba M., et al.
Publicado: (2019)

Cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
por: Hallinen, Taru A., et al.
Publicado: (2010)

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
por: Strand, Vibeke, et al.
Publicado: (2017)

Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis
por: Low, Audrey S L, et al.
Publicado: (2017)

Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients’ offspring
por: Smeele, Hieronymus T W, et al.
Publicado: (2022)

Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
por: Balanescu, Andra-Rodica, et al.
Publicado: (2022)

Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study
por: Song, Yeo-Jin, et al.
Publicado: (2022)

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
por: Tanaka, Yoshiya, et al.
Publicado: (2015)

Small GTP-binding protein Rho-mediated signaling promotes proliferation of rheumatoid synovial fibroblasts
por: Nakayamada, Shingo, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_an7r2q73nco2g6c7se3f2o0qts